SPRO - Spero Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.46
+0.03 (+0.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.43
Open11.42
Bid11.26 x 1300
Ask12.15 x 800
Day's Range11.05 - 11.72
52 Week Range9.66 - 19.00
Volume130,386
Avg. Volume110,060
Market Cap208.088M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-17.82
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development

    CAMBRIDGE, Mass., July 16, 2018 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to treat multi-drug resistant bacterial infections, today announced that it was awarded funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA). The funding will support the further clinical development of Spero’s oral carbapenem product candidate, SPR994, for the treatment of complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria.

  • GlobeNewswire8 days ago

    Spero Therapeutics Announces Pricing of Securities Offering

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock.  The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00. The gross proceeds to Spero from this offering are $75,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Spero. All of the shares in the offering will be sold by Spero.  In addition, Spero has granted the underwriters a 30-day option to purchase up to an additional 567,000 shares of common stock at the public offering price, less the underwriting discount.  The offering is expected to close on July 17, 2018, subject to customary closing conditions.

  • GlobeNewswire11 days ago

    Spero Therapeutics Announces Proposed Offering of Common Stock

    Spero Therapeutics, Inc. (SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.  All of the shares in the offering will be sold by Spero.  In addition, Spero expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. are serving as joint book-running managers for the offering.  Oppenheimer & Co. Inc. is acting as lead manager for the offering, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire11 days ago

    Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

    Spero Therapeutics, Inc. (SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to treat multi-drug resistant bacterial infections, today reported positive results from an interim analysis of its ongoing single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical trial of SPR994, its investigational oral carbapenem product candidate designed for the treatment of Gram-negative infections, in healthy volunteers. The data demonstrate that SPR994 has a favorable safety, pharmacokinetic and pharmacodynamic profile that supports the advancement of SPR994 to a pivotal Phase 3 clinical trial at a 300 mg dose administered three times per day (TID). “We are encouraged by interim results of the Phase 1 trial that we believe show compelling pharmacokinetics, safety and tolerability for SPR994,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics.

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within Jabil, Gladstone Investment, Spero Therapeutics, Jagged Peak Energy, Sabre, and Zions — New Research Emphasizes Economic Growth

    NEW YORK, June 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Jabil, ...

  • PR Newswirelast month

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • GlobeNewswirelast month

    Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018

    Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’ s broad spectrum of activity and equivalence to IV carbapenems. CAMBRIDGE, Mass., June 05, 2018-- ...

  • GlobeNewswire2 months ago

    Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the Jefferies 2018 Healthcare Conference on Wednesday, June 6th, 2018 at 4:30 PM ET in New York, New York. Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. The Company’s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.

  • GlobeNewswire2 months ago

    Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform

    SPR741 Phase 1 b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development. Phase 1 b data demonstrates pharmacokinetic compatibility and tolerability ...

  • Benzinga2 months ago

    Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

    The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...

  • GlobeNewswire2 months ago

    Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update

    CAMBRIDGE, Mass., May 10, 2018-- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug ...

  • GlobeNewswire3 months ago

    Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May

    CAMBRIDGE, Mass., May 01, 2018-- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant ...

  • ACCESSWIRE3 months ago

    Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Dynavax Technologies Corp. (NASDAQ: DVAX) ("Dynavax"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DVAX as the Company's latest news hit the wire. On April 23, 2018, the Company announced that the Centers for Disease Control and Prevention (CDC) has published the Advisory Committee of Immunization Practices' (ACIP) Recommendations for the use of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for adults in the US, in the Morbidity and Mortality Weekly Report (MMWR) dated April 19, 2018.

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • These Alphabet-Backed Biotech Startups Went Public In 1Q18
    Market Realist3 months ago

    These Alphabet-Backed Biotech Startups Went Public In 1Q18

    What to Watch for in Alphabet's 1Q18 ResultsVerily selected for FDA pilot

  • Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry
    Simply Wall St.4 months ago

    Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Spero Therapeutics Inc’s (NASDAQ:SPRO) track record on a high level, toRead More...

  • PR Newswire6 months ago

    Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

    WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.